

SOLIPHEN 15 mg tablet for dogs

Authorised

- Phenobarbital

Product identification

Medicine name:

SOLIPHEN 15 mg tablet for dogs

Active substance:

Phenobarbital

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Phenobarbital

15.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN03AA02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Belgium

Package description:

(ID2) 96 Tablet: Box (Cardboard) with 8 Blister (PolyVinyl Chloride) each with 12 Tablet, closed with Foil (Aluminium)

(ID1) 60 Tablet: Box (Cardboard) with 5 Blister (PolyVinyl Chloride) each with 12 Tablet, closed with Foil (Aluminium)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Domes Pharma

Marketing authorisation date:

16/05/2022

Manufacturing sites for batch release:

Europeenne De Pharmacotechnie Europhartech

Responsible authority:

Federal Agency For Medicines And Health Products

Authorisation number:

BE-V599324

Date of authorisation status change:

17/06/2022

Reference member state:

Germany

Procedure number:

DE/V/0305/002

Concerned member states:

Austria Belgium France Italy Luxembourg Netherlands Portugal Spain
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

7004476-paren-20220316.pdf